Publications by authors named "Anke Post"

Claim this Profile
D
Drug Development.
Lara Herriott, Mark Coles, Eamonn Gaffney, Nicolas Fournier, Nicolas Sanchez, Anke Post

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation.
Amy C Beckenstrom, Preciosa M Coloma, Gerard R Dawson, Ailidh K Finlayson, Asad Malik, Anke Post

Neurosci Biobehav Rev· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment.
Gerard R Dawson, Anke Post, Trevor S Smart, Michael Browning, Catherine J Harmer

J Psychopharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Gennaro Pagano, Frank G Boess, Kirsten I Taylor, Benedicte Ricci, Brit Mollenhauer, Anke Post

Front Neurol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease.
Amy C Bilderbeck, Brenda W J H Penninx, Celso Arango, Nic van der Wee, René Kahn, Anke Post

Neurosci Biobehav Rev· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer's disease.
Nic J A van der Wee, Amy C Bilderbeck, Maria Cabello, Jose L Ayuso-Mateos, Ilja M J Saris, Anke Post

Neurosci Biobehav Rev· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.
Jeffrey M Witkin, Linda M Rorick-Kehn, Mark J Benvenga, Benjamin L Adams, Scott D Gleason, Anke Post

Pharmacol Res Perspect· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.
Anke Post, Trevor S Smart, Kimberley Jackson, Joanne Mann, Richard Mohs

Alcohol Clin Exp Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Anke Post, Trevor S Smart, Judith Krikke-Workel, Gerard R Dawson, Catherine J Harmer

Neuropsychopharmacology· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Anke Post, Trevor S Smart, Judith Krikke-Workel, Gerard R Dawson, Catherine J Harmer

Neuropsychopharmacology· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review.
Michael E Thase, Harald Murck, Anke Post

Prim Care Companion J Clin Psychiatry· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Stephen M Stahl, Maurizio Fava, Madhukar H Trivedi, Angelika Caputo, Amy Shah, Anke Post

J Clin Psychiatry· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
John Zajecka, Alan Schatzberg, Stephen Stahl, Amy Shah, Angelika Caputo, Anke Post

J Clin Psychopharmacol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
Ann C Childress, Thomas Spencer, Frank Lopez, Ortrud Gerstner, Anuradha Thulasiraman, Anke Post

J Child Adolesc Psychopharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression.
Anke Post, Nibal Ackl, Monika Rücker, Yvonne Schreiber, Elisabeth B Binder

Biol Psychiatry· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919).
Anke Post, Frauke Ohl, Osborne F X Almeida, Elisabeth B Binder, Monika Rücker

Psychopharmacology (Berl)· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity.
Anke Post, Monika Rücker, Frauke Ohl, Manfred Uhr, Florian Holsboer

Neuropsychopharmacology· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis